100%
#0KF3Palatin Technologies Inc.
as of 2024-12-20
1M : 10.8%
6M : -43.41%
1Yr : -59.56%
51.50%
Company Profile
Name: Palatin Technologies Inc.
Code: 0KF3
Exchange: LSE
Country: UK
ISIN:
Sector:
Industry:
Address: Cedar Brook Corporate Center, Cranbury, NJ, United States, 08512
Fulltime Employees: 30.00

Profile Description:

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.

Financial News Sentiment

News Sentiment